154 related articles for article (PubMed ID: 22067661)
1. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy.
Clifford DB; Simpson DM; Brown S; Moyle G; Brew BJ; Conway B; Tobias JK; Vanhove GF;
J Acquir Immune Defic Syndr; 2012 Feb; 59(2):126-33. PubMed ID: 22067661
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
Simpson DM; Brown S; Tobias J;
Neurology; 2008 Jun; 70(24):2305-13. PubMed ID: 18541884
[TBL] [Abstract][Full Text] [Related]
3. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study.
Simpson DM; Brown S; Tobias JK; Vanhove GF;
Clin J Pain; 2014 Feb; 30(2):134-42. PubMed ID: 23446088
[TBL] [Abstract][Full Text] [Related]
4. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J;
Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
Webster LR; Malan TP; Tuchman MM; Mollen MD; Tobias JK; Vanhove GF
J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
[TBL] [Abstract][Full Text] [Related]
6. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.
Webster LR; Tark M; Rauck R; Tobias JK; Vanhove GF
BMC Neurol; 2010 Oct; 10():92. PubMed ID: 20937130
[TBL] [Abstract][Full Text] [Related]
7. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials.
Brown S; Simpson DM; Moyle G; Brew BJ; Schifitto G; Larbalestier N; Orkin C; Fisher M; Vanhove GF; Tobias JK
AIDS Res Ther; 2013 Jan; 10(1):5. PubMed ID: 23351618
[TBL] [Abstract][Full Text] [Related]
8. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
Irving G; Backonja M; Rauck R; Webster LR; Tobias JK; Vanhove GF
Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
Simpson DM; Gazda S; Brown S; Webster LR; Lu SP; Tobias JK; Vanhove GF;
J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
[TBL] [Abstract][Full Text] [Related]
10. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
Simpson DM; Estanislao L; Brown SJ; Sampson J
J Pain Symptom Manage; 2008 Mar; 35(3):299-306. PubMed ID: 17959343
[TBL] [Abstract][Full Text] [Related]
11. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
Backonja MM; Malan TP; Vanhove GF; Tobias JK;
Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
[TBL] [Abstract][Full Text] [Related]
12. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
Noto C; Pappagallo M; Szallasi A
Curr Opin Investig Drugs; 2009 Jul; 10(7):702-10. PubMed ID: 19579176
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Webster LR; Peppin JF; Murphy FT; Lu B; Tobias JK; Vanhove GF
Diabetes Res Clin Pract; 2011 Aug; 93(2):187-197. PubMed ID: 21612836
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain.
Webster LR; Peppin JF; Murphy FT; Tobias JK; Vanhove GF
J Pain Res; 2012; 5():7-13. PubMed ID: 22328830
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain.
Peppin JF; Majors K; Webster LR; Simpson DM; Tobias JK; Vanhove GF
J Pain Res; 2011; 4():385-92. PubMed ID: 22247621
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia.
Webster LR; Nunez M; Tark MD; Dunteman ED; Lu B; Tobias JK; Vanhove GF
BMC Anesthesiol; 2011 Dec; 11():25. PubMed ID: 22182397
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
Babbar S; Marier JF; Mouksassi MS; Beliveau M; Vanhove GF; Chanda S; Bley K
Ther Drug Monit; 2009 Aug; 31(4):502-10. PubMed ID: 19494795
[TBL] [Abstract][Full Text] [Related]
18. Topical capsaicin (high concentration) for chronic neuropathic pain in adults.
Derry S; Sven-Rice A; Cole P; Tan T; Moore RA
Cochrane Database Syst Rev; 2013 Feb; (2):CD007393. PubMed ID: 23450576
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy.
Simpson DM; Rice AS; Emir B; Landen J; Semel D; Chew ML; Sporn J
Pain; 2014 Oct; 155(10):1943-54. PubMed ID: 24907403
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.
Mankowski C; Poole CD; Ernault E; Thomas R; Berni E; Currie CJ; Treadwell C; Calvo JI; Plastira C; Zafeiropoulou E; Odeyemi I
BMC Neurol; 2017 Apr; 17(1):80. PubMed ID: 28431564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
